In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anju Ghangurde

Anju Ghangurde is Scrip's Deputy Asia Editor and has about two decades of experience in journalism including stints at India's mainstream financial dailies -The Economic Times, The Hindu Business Line and The Financial Express.  She covers a broad range of issues including competition and collaboration between generics and innovator firms, drug pricing and the evolving regulatory and legal framework in the region. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.

Latest From Anju Ghangurde

Onward Ho: Biocon Signals Glargine Build Up, US Biosimilars Pricing ‘Sanity’

Biocon anticipates significant US uptake of its Viatris-partnered interchangeable insulin glargine biosimilar on the back of commercial arrangements in place and expects to "move the market" in 2022. All eyes are also on the trajectory of biosimilar insulin aspart, which received a CRL from the US FDA.

Sales & Earnings Strategy

Onward Ho: Biocon Signals Glargine Build Up, US Biosimilars Pricing ‘Sanity’

Biocon anticipates significant US uptake of its Viatris-partnered interchangeable insulin glargine biosimilar on the back of commercial arrangements in place and expects to "move the market" in 2022.  All eyes are also on the trajectory of biosimilar insulin aspart, which received a CRL from the US FDA.

Commercial Biosimilars

Can Novo’s Oral Semaglutide Shake Up Indian Diabetes Segment?

Novo Nordisk's oral semaglutide debuts in India at a monthly cost of about $135 and promises to transform diabetes management in the country. Will it impact the SGLT-2 inhibitor class and potentially cannibalize injectable GLP-1 receptor agonists?

India Commercial

Respiratory Plus: Cipla Shapes Future In New Age Platforms, Devices, Diagnostics

The next chapter of Cipla’s innovation journey goes beyond its core respiratory thrust to include new platforms spanning areas such as peptides, where it has seen its first major approval in the US and has multiple programs lined up. Devices and diagnostics are among the other avenues being explored as the Indian company seeks to bring more patients into the “funnel”.

Commercial Strategy

Sanofi India Chief Departs, Sets Transformative Path

Sanofi India's managing director is moving on after an eventful innings that saw the company re-orient operations, moving out of certain non-strategic areas to focus on core therapies. Pre-pandemic early digital adoption appears to have played out well too for the French group’s listed Indian arm.

Commercial India

2021 Saw India Enable Accelerated Regulatory Pathways – Can It Become The Norm?

India saw a raft of vaccine and drug approvals in 2021, backed by pandemic-related accelerated regulatory processes, and outlined its intent to step up biopharma innovation in the country.  Pharma wants some of the regulatory flexibility to stay, though experts are seeking increased transparency in the overall approach.

Approvals Drug Approval Standards
See All
UsernamePublicRestriction

Register